ZIM Laboratories Limited

ZIM Laboratories Limited (ZIM) has been listed on the BSE Main Board on June 8, 2018. The book value price of ZIM was Rs 160 per equity share. Anwar Daud, Chairman & Managing Director, told media persons here recently that ZIM is amongst the few global companies to have developed and commercialized the oral film technology, besides also being the first Indian company to manufacture multi-layer thin films that contain more than one API on a single thin strip. Describing ZIM Laboratories as a unique R&D-centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS), he said ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines and the company listing on BSE on June 8 had a price discovery as per trading on the bourses. Original Article

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries. Original Article  

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology. The first Indian company to manufacture multi-layer thin films - that contain more than one API on a single thin strip. Company to get listed on BSE Mainboard on June 08, 2018. The book value price of ZIM is Rs.160/- per equity share. ZIM got listed on OTC Exchange on India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS). Original Article  

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology. The first Indian company to manufacture multi-layer thin films – that contain more than one API on a single thin strip. Company to get listed on BSE Mainboard on June 08, 2018 . The book value price of ZIM is Rs. 160/-  per equity share ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. Original Article

Nagpur-based pharmaceuticals company Zim Laboratories will list on BSE on Friday, June 8. Zim Labs was trading on the OTC Exchange Of India before the Securities Exchange Board of India (SEBI) withdrew its recognition of it in March 2015. The company was recently by allowed SEBI to list on the main board of BSE.  This listing will provide an exit to some of its existing shareholders. The book value of Zim Labs, promoted by Anwar Daud, is Rs 160 per equity share. Daud and his family own 54 percent stake in the company, and private equity firm Ashmore Alchemy India Advisors owns around 22 percent. The rest is owned by minority shareholders. Original Article  

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries. Original Article  

ZIM Laboratories (ZIM), an R&D centred pharmaceutical company today said it will list its shares on BSE on Friday. ZIM got listed on OTC Exchange of India in 1994, following the Sebi guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. The book value price is Rs 160 per equity share. Original Article

The company was allowed recently by SEBI to list on the BSE main board. This listing will provide an exit to existing shareholders. Original Article  

Zim Labs was trading on the OTC Exchange Of India before the Securities Exchange Board of India (SEBI) withdrew its recognition of it in March 2015. The company was recently by allowed SEBI to list on the main board of BSE. The book value of Zim Labs, promoted by Anwar Daud, is Rs 160 per equity share. Started in 1989, Zim clocked a profit after tax of Rs 18 crore on revenue of Rs 275 crore in FY18. Zim has developed and commercialised the complex oral film technology and plans to launch multi-layer thin films that contain more than one API on a single thin strip in coming months. Original Article  

ZIM Laboratories to List on BSE on Friday *ZIM Laboratories (ZIM), an R&D centered pharmaceutical company today said it will list its shares on BSE on Friday. ZIM got listed on OTC Exchange of India in 1994, following the Sebi guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. The book value price is Rs 160 per equity share. Original Article

ZIM Laboratories to get listed on BSE Mainboard on June 08, 2018 at a book value price is Rs. 160/- per equity share ZIM is amongst a few companies globally to have developed and commercialized the oral thin film technology.The first Indian company to manufacture multi layer thin films that contains more than one API on a single thin strip. Company to get listed on BSE Mainboard on June 08, 2018.The book value price of ZIM is Rs.160/- per equity share. ZIM laboratories Limited (ZIM) - is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS). Original Article  

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology. The company is to get listed on BSE Mainboard on June 08, 2018. The book value price of ZIM is Rs. 160/- per equity share. ZIM Laboratories Limited (ZIM) is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. Original Article

Nagpur based Zim Laboratories Limited, a leading provider of new drug delivery systems, will be listing on Bombay Stock Exchange (BSE) Main Board on June 8 and will have a price discovery as per trading on the bourses. It is likely to fetch attractive returns for existing shareholders. The book value price of Zim Labs, promoted by technocrate Dr Anwar Daud is Rs 160 per equity share. Daud and his family has 54 per cent stake in ZIM Labs and the private equity partner Ashmore Alchemy India Advisors has about 22 per cent. Rest is with minority shareholders. Original Article

Nagpur-based Zim Laboratories will invest Rs 35 crores for setting up research lab and small manufacturing unit in Nagpur both for the regulated and Rest of the World (RoW) markets. Funds will be arranged from internal accrual and term loans. Both the new units are likely to be commissioned in next six months. On the sidelines of a press conference in Mumbai, Dr Anwar Daud, MD, Zim Laboratories said, “Our new research lab will specialise in complex generics and we will hire around 45-50 scientists. We will also set up a small batch manufacturing unit for high value and small volume formulation facility, which will be EU-GMP compliant.” Original Article

Nagpur-based pharmaceuticals company Zim Laboratories will list on BSE on Friday, June 8.Zim Labs was trading on the OTC Exchange Of India before the Securities Exchange Board of India (SEBI) withdrew its recognition of it in March 2015. The company was recently by allowed SEBI to list on the main board of BSE.  This listing will provide an exit to some of its existing shareholders. Original Article

ZIM Laboratories  (ZIM), an R&D centred pharmaceutical company today  said it will list its shares on BSE on Friday. ZIM got listed on  OTC Exchange of India  in 1994, following the Sebi guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. The book value price is Rs 160 per equity share. Original Article

Thin films are ideal dosage form for pediatric,generic,dysphagic,mentally challenged and bed ridden patients.These films are thin,flat,elegant,rectangular shaped dosage forms that can be delivered by either oral sublingual or buccal route.In the market, most of the available products are single layered and belong to category of orally dissolving films.A few belong to sublingual and buccal category. Original Article

Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities. Nagpur-based Zim Laboratories is a non-descript drug company with turnover in excess of Rs 250 crore. In the past two decades, Zim has been silently working on developing innovative and differentiated pharmaceutical products or specialty generic complex drugs. Recently, it developed a new product, Orally Disintegrating Strip (ODS) formulations up to 100 milligram, based on a patented oral thin film technology. These films, when placed on the tongue, adhere to the tongue mucosa and disintegrate almost instantaneously. There are only some 10 companies across the globe with this technology, but they are not able to grab a big share of the market due to prohibitive manufacturing costs. "With our technology, we can offer thin films at a price near to that of an oral tablet," says Anwar S. Daud, Managing Director of Zim Laboratories. Original Article ...

Mumbai:  In a bid to provide relief to bedridden patient from gulping down several medicines on a daily basis, a Nashik-based pharmaceutical company has procured a first-of-its-kind multi-layer oral thin films (OTF) or drug strips that melt when kept on the tongue. A senior health official said this drug delivery method has already received approval from Central Drugs Standard Control Organisation and will be available at a similar price as the tables. They would first start manufacturing medicines for asthma and allergy on a trial basis. The officials said most OTFs are extremely expensive due to which common people can’t afford them. These films are useful for patients suffering cancer, asthma, cardiac ailments.  “We decided to work on developing multi-layer oral films after getting a good response from patients on the one-layer oral films. Later, the Food and Drugs Administration (FDA) approved the product which would soon be released in the market,” said Dr Anwar Daud,...

Medicines administered to bedridden patients in the form of oral thin films might get a whole lot cheaper in India soon. A Nagpur-based pharmaceutical company has produced the country's first multi-layer oral thin films (OTF), making the otherwise imported medicines inexpensive and more accessible. The India-developed film, made by Zim Laboratories, has already received approval from Central Drugs Standard Control Organization (CDSCO) and will be available at a price similar to that of the tablets. In 2015, CDSCO gave the lab the approval manufacture and market OTFs of two medicines: Montelukast sodium and Levocetirizine Dihydrochloride used for treatment of allergies and asthma (mid-day has a copy). These melt-in-the-mouth films are usually given to bedridden patients who cannot gulp down tablets. They are especially useful for those suffering from cancer, asthma and cardiac ailments. Original Article